Skip to main content
. 2002 Aug 5;158(3):497–506. doi: 10.1083/jcb.200201116

Table I. The lateral mobility of GFP-tagged fusion proteins stably expressed in M3/18 or transiently expressed in tsBN7 cells.

Cell line Construct Growth temperature Treatment Diffusion constant
(D eff), μm2/s ± SD
Mobile fraction
(Mr), % ± SD
n
M3/18 GFP–Dad1 39.5°C 0.049 ± 0.010 87.9 ± 7.4 18
Cycloheximide 0.044 ± 0.013 89.6 ± 8.1 8
NaCl 0.251 ± 0.071 94.5 ± 5.6 5
Puromycin 0.131 ± 0.058 89.4 ± 5.7 25
Tunicamycin 0.048 ± 0.016 89.1 ± 2.5 10
tsBN7 LBR–GFP 34°C 0.331 ± 0.054 99.6 ± 5.2 4
NaCl 0.328 ± 0.032 97.8 ± 1.3 9
Puromycin 0.335 ± 0.029 96.3 ± 3.6 7
39.5°C 0.331 ± 0.031 89.6 ± 2.9 8
Dad1–GFP 34°C 0.315 ± 0.064 93.3 ± 5.2 7
39.5°C NA NA 15
34°C 0.178 ± 0.037 89.5 ± 5.9 10
GFP–Dad1 39.5°C 0.140 ± 0.024 88.9 ± 1.9 10

Means ± SD denotes standard deviation of values for D eff and M f for recovery of fluorescence after photobleaching. The cells were grown overnight in glass-bottomed dishes for cell culture and pretreated as indicated with cycloheximide (80 μM for 30 min), NaCl (an extra 150 mM for 10 min), puromycin (100 μM for 15 min), or tunicamycin (1 μg/ml for 4 h) before the FRAP experiments. NA denotes that no reliable data were obtained (see Results for details).

HHS Vulnerability Disclosure